BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang C, Wen J, Li Z, Fan J. Efficacy and safety of lanthanum carbonate on chronic kidney disease-mineral and bone disorder in dialysis patients: a systematic review. BMC Nephrol. 2013;14:226. [PMID: 24134531 DOI: 10.1186/1471-2369-14-226] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 4.2] [Reference Citation Analysis]
Number Citing Articles
1 Vekeman J, Torres J, David CE, Van de Perre E, Wissing KM, Letavernier E, Bazin D, Daudon M, Pozdzik A, Tielens F. In Search of an Efficient Complexing Agent for Oxalates and Phosphates: A Quantum Chemical Study. Nanomaterials (Basel) 2021;11:1763. [PMID: 34361148 DOI: 10.3390/nano11071763] [Reference Citation Analysis]
2 Tsuchiya K, Akihisa T. The Importance of Phosphate Control in Chronic Kidney Disease. Nutrients 2021;13:1670. [PMID: 34069053 DOI: 10.3390/nu13051670] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Salam SN, Khwaja A, Wilkie ME. Pharmacological Management of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease. Drugs 2016;76:841-52. [PMID: 27142279 DOI: 10.1007/s40265-016-0575-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
4 Cernaro V, Santoro D, Lacquaniti A, Costantino G, Visconti L, Buemi A, Buemi M. Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide. Int J Nephrol Renovasc Dis. 2016;9:11-19. [PMID: 26893577 DOI: 10.2147/ijnrd.s78040] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 3.2] [Reference Citation Analysis]
5 Yabuki K, Haratake J, Tsuda Y, Shiba E, Harada H, Yorita K, Uchihashi K, Matsuyama A, Hirata K, Hisaoka M. Lanthanum-Induced Mucosal Alterations in the Stomach (Lanthanum Gastropathy): a Comparative Study Using an Animal Model. Biol Trace Elem Res. 2018;185:36-47. [PMID: 29302869 DOI: 10.1007/s12011-017-1235-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
6 Kemper MJ, van Husen M. Renal osteodystrophy in children: pathogenesis, diagnosis and treatment. Current Opinion in Pediatrics 2014;26:180-6. [DOI: 10.1097/mop.0000000000000061] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 1.4] [Reference Citation Analysis]
7 Phannajit J, Wonghakaeo N, Takkavatakarn K, Asawavichienjinda T, Praditpornsilpa K, Eiam-Ong S, Susantitaphong P. The impact of phosphate lowering agents on clinical and laboratory outcomes in chronic kidney disease patients: a systematic review and meta-analysis of randomized controlled trials. J Nephrol 2021. [PMID: 34061337 DOI: 10.1007/s40620-021-01065-3] [Reference Citation Analysis]
8 Hutchison AJ, Wilson RJ, Garafola S, Copley JB. Lanthanum carbonate: safety data after 10 years. Nephrology (Carlton) 2016;21:987-94. [PMID: 27479781 DOI: 10.1111/nep.12864] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 6.4] [Reference Citation Analysis]
9 Olowu WA. Pre-treatment considerations in childhood hypertension due to chronic kidney disease. World J Nephrol 2015; 4(5): 500-510 [PMID: 26558187 DOI: 10.5527/wjn.v4.i5.500] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
10 Chan S, Au K, Francis RS, Mudge DW, Johnson DW, Pillans PI. Phosphate binders in patients with chronic kidney disease. Aust Prescr 2017;40:10-4. [PMID: 28246429 DOI: 10.18773/austprescr.2017.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
11 Shang JY, Zhan P, Jiang C, Zou Y, Liu H, Zhang B, Dai M. Inhibitory Effects of Lanthanum Chloride on Wear Particle-Induced Osteolysis in a Mouse Calvarial Model. Biol Trace Elem Res 2016;169:303-9. [PMID: 26105543 DOI: 10.1007/s12011-015-0364-x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
12 Li J, Wang L, Han M, Xiong Y, Liao R, Li Y, Sun S, Maharjan A, Su B. The role of phosphate-containing medications and low dietary phosphorus-protein ratio in reducing intestinal phosphorus load in patients with chronic kidney disease. Nutr Diabetes 2019;9:14. [PMID: 30944300 DOI: 10.1038/s41387-019-0080-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
13 Gros B, Galán A, González-Parra E, Herrero JA, Echave M, Vegter S, Tolley K, Oyagüez I. Cost effectiveness of lanthanum carbonate in chronic kidney disease patients in Spain before and during dialysis. Health Econ Rev 2015;5:49. [PMID: 26062537 DOI: 10.1186/s13561-015-0049-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
14 Vallée M, Weinstein J, Battistella M, Papineau R, Moseley D, Wong G. Multidisciplinary Perspectives of Current Approaches and Clinical Gaps in the Management of Hyperphosphatemia. Int J Nephrol Renovasc Dis 2021;14:301-11. [PMID: 34393498 DOI: 10.2147/IJNRD.S318593] [Reference Citation Analysis]
15 Iwamoto N, Sato N, Nishida M, Hashimoto T, Kobayashi H, Yamazaki S, Okino K, Nishimura M, Takatani T, Okamoto Y, Nakanouchi T, Koyama M, Adachi N, Ninomiya K, Mabuchi H, Iseki K. Low parathyroid hormone levels after parathyroidectomy reduce cardiovascular mortality in chronic hemodialysis patients. Clin Exp Nephrol 2016;20:808-14. [DOI: 10.1007/s10157-015-1208-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
16 Sharaf El Din UAA, Salem MM, Abdulazim DO. Vascular calcification: When should we interfere in chronic kidney disease patients and how? World J Nephrol 2016; 5(5): 398-417 [PMID: 27648404 DOI: 10.5527/wjn.v5.i5.398] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
17 Yu C, Gong J, Yin FL, Huang J, Zhang TL, Wang K. Influences of LaCl3 on the mineral phase transformation during osteoblast mineralization in vitro. J Environ Sci (China) 2017;51:88-96. [PMID: 28115154 DOI: 10.1016/j.jes.2016.06.029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
18 Tatsuta T, Mikami T, Chinda D, Akitaya K, Igarashi S, Hasui K, Kikuchi H, Hiraga H, Sawaya M, Sakuraba H, Shimoyama T, Haga T, Kijima H, Fukuda S. Case report of lanthanum deposition in the esophagus. Clin J Gastroenterol 2020;13:683-7. [PMID: 31873845 DOI: 10.1007/s12328-019-01085-4] [Reference Citation Analysis]
19 Zhai C, Yang X, Sun J, Wang R. Efficacy and safety of lanthanum carbonate versus calcium-based phosphate binders in patients with chronic kidney disease: a systematic review and meta-analysis. Int Urol Nephrol 2015;47:527-35. [DOI: 10.1007/s11255-014-0876-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
20 Floege J. Phosphate binders in chronic kidney disease: a systematic review of recent data. J Nephrol 2016;29:329-40. [DOI: 10.1007/s40620-016-0266-9] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 6.2] [Reference Citation Analysis]
21 Peter WLS, Wazny LD, Weinhandl E, Cardone KE, Hudson JQ. A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs? Drugs 2017;77:1155-86. [DOI: 10.1007/s40265-017-0758-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
22 Anand A, Yoshida S, Aoyagi H. Tailored synbiotic powder (functional food) to prevent hyperphosphataemia (kidney disorder). Sci Rep 2021;11:16485. [PMID: 34389737 DOI: 10.1038/s41598-021-95176-3] [Reference Citation Analysis]
23 Negri AL, Ureña Torres PA. Iron-based phosphate binders: do they offer advantages over currently available phosphate binders? Clin Kidney J 2015;8:161-7. [PMID: 25815172 DOI: 10.1093/ckj/sfu139] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
24 Lioufas N, Toussaint ND, Pedagogos E, Elder G, Badve SV, Pascoe E, Valks A, Hawley C; IMPROVE-CKD Writing Committee. Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study. BMJ Open 2019;9:e024382. [PMID: 30796122 DOI: 10.1136/bmjopen-2018-024382] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
25 Tonooka A, Uda S, Tanaka H, Yao A, Uekusa T. Possibility of lanthanum absorption in the stomach. Clin Kidney J. 2015;8:572-575. [PMID: 26413283 DOI: 10.1093/ckj/sfv062] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
26 Yang X, Bai Q, Li Y, Liu H, Guo H, Zhang X. Comparative Efficacy and Safety of Phosphate Binders in Hyperphosphatemia Patients With Chronic Kidney Disease. JPEN J Parenter Enteral Nutr 2018;42:766-77. [PMID: 28777915 DOI: 10.1177/0148607117715440] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
27 Sharaf El Din UAA, Salem MM, Abdulazim DO. Stop chronic kidney disease progression: Time is approaching. World J Nephrol 2016; 5(3): 258-273 [PMID: 27152262 DOI: 10.5527/wjn.v5.i3.258] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
28 Di Y, Wasan EK, Cawthray J, Syeda J, Ali M, Cooper DML, Al-Dissi A, Ashjaee N, Cheng W, Johnston J, Weekes DM, Kostelnik TI, Orvig C, Wasan KM. Evaluation of La(XT), a novel lanthanide compound, in an OVX rat model of osteoporosis. Bone Rep 2021;14:100753. [PMID: 33665236 DOI: 10.1016/j.bonr.2021.100753] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Lin YC, Lin YC, Hsu CY, Kao CC, Chang FC, Chen TW, Chen HH, Hsu CC, Wu MS; Taiwan Society of Nephrology. Effect Modifying Role of Serum Calcium on Mortality-Predictability of PTH and Alkaline Phosphatase in Hemodialysis Patients: An Investigation Using Data from the Taiwan Renal Registry Data System from 2005 to 2012. PLoS One 2015;10:e0129737. [PMID: 26107510 DOI: 10.1371/journal.pone.0129737] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
30 Lioufas NM, Pascoe EM, Hawley CM, Elder GJ, Badve SV, Block GA, Johnson DW, Toussaint ND. Systematic Review and Meta-Analyses of the Effects of Phosphate-Lowering Agents in Nondialysis CKD. J Am Soc Nephrol 2022;33:59-76. [PMID: 34645696 DOI: 10.1681/ASN.2021040554] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Murakami N, Yoshioka M, Iwamuro M, Nasu J, Nose S, Shiode J, Okada H, Yamamoto K. Clinical Characteristics of Seven Patients with Lanthanum Phosphate Deposition in the Stomach. Intern Med. 2017;56:2089-2095. [PMID: 28781325 DOI: 10.2169/internalmedicine.8720-16] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
32 Barreto FC, Barreto DV, Massy ZA, Drüeke TB. Strategies for Phosphate Control in Patients With CKD. Kidney Int Rep 2019;4:1043-56. [PMID: 31440695 DOI: 10.1016/j.ekir.2019.06.002] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 9.3] [Reference Citation Analysis]
33 Makowka A, Nowicki M. Different Effect of Lanthanum Carbonate and Sevelamer Hydrochloride on Calcium Balance in Patients with Moderate to Advanced Chronic Kidney Disease. Ther Clin Risk Manag 2021;17:1145-51. [PMID: 34754193 DOI: 10.2147/TCRM.S330649] [Reference Citation Analysis]
34 Gutekunst L. An Update on Phosphate Binders: A Dietitian's Perspective. J Ren Nutr 2016;26:209-18. [PMID: 26920090 DOI: 10.1053/j.jrn.2016.01.009] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
35 Locatelli F, Del Vecchio L, Violo L, Pontoriero G. Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a comparison of safety profiles. Expert Opin Drug Saf. 2014;13:551-561. [PMID: 24702470 DOI: 10.1517/14740338.2014.907791] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
36 Zhang W, Xu J, Li P, Gao X, Zhang W, Wang H, Tang B. Treatment of hyperphosphatemia based on specific interactions between phosphorus and Zr(iv) active centers of nano-MOFs. Chem Sci 2018;9:7483-7. [PMID: 30319748 DOI: 10.1039/c8sc02638f] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 2.3] [Reference Citation Analysis]
37 Yu L, Xiong J, Guo L, Miao L, Liu S, Guo F. The effects of lanthanum chloride on proliferation and apoptosis of cervical cancer cells: involvement of let-7a and miR-34a microRNAs. Biometals 2015;28:879-90. [PMID: 26209160 DOI: 10.1007/s10534-015-9872-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
38 Iwamuro M, Urata H, Tanaka T, Kawano S, Kawahara Y, Kimoto K, Okada H. Lanthanum Deposition in the Stomach in the Absence of Helicobacter pylori Infection. Intern Med. 2018;57:801-806. [PMID: 29225268 DOI: 10.2169/internalmedicine.9665-17] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
39 Iwamuro M, Urata H, Tanaka T, Kawano S, Kawahara Y, Okada H. Frequent Involvement of the Duodenum with Lanthanum Deposition: A Retrospective Observational Study. Intern Med. 2019;58:2283-2289. [PMID: 31118380 DOI: 10.2169/internalmedicine.2398-18] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]